Interferons and interleukins for cancer treatment
In immunotherapy treatment, oncologists use antibodies, vaccines, immunotoxins, bacteria, immune cells, and cytokines to stimulate the immune system and to reduce the risk of cancer recurring. Currently, just two cytokines (IFNα and IL-2) are employed by doctors to cure various cancer diseases; other cytokines are under evaluation in various phases of preclinical and clinical trials.
Interferons and interleukins are members of the cytokine class – the regulatory or signaling biomolecules produced by the body’s immune system to act on the cells locally. Interferons (IFNα, IFNβ, and IFNγ) are proteins that help to fight infections and cancer diseases. IFNα and IFNβ are generated by many of the body’s cells after viral infection and are involved in the innate immune response. IFNα and IFNβ increase a resistance of normal cells to natural killer (NK) cells and make cancer cells more vulnerable to killing by cytotoxic T cells. Interleukin-2 (IL-2) stimulates a growth and an activity of T cells; lymphocytes treated with this interleukin dramatically enhance their antitumor activity.
Interferon alfa-2b (Intron® A), Interferon alfa-2a (Roferon® A)
These two drugs are synthetic versions of IFNα which is used to treat bladder cancer, melanoma, chronic myelogenous leukemia, multiple myeloma, hairy cell leukemia, Kaposi’s sarcoma, follicular non-Hodgkin’s lymphoma, and condyloma acuminata, chronic myelogenous leukemia, kidney cancer, carcinoid syndrome, islet cell tumor, multiple myeloma, non-follicular non-Hodgkin’s lymphoma, cutaneous T-cell lymphoma, desmoid tumor.
How it works. IFNα increases a resistance of normal cells to NK cells, and make cancer cells more vulnerable to killing by cytotoxic T cells. Interferon blocks a growth and multiplying of cancer cells, and encourages cancer cells to send out substances that attract immune cells.
How is it made. It is synthetically produced by recombinant DNA techniques in bacteria E.coli with inserted an IFNα gene from human white blood cells.
How it is given. Via injection under the skin, through a vein, into a muscle (3-7 times a week), and through the urethra and directly into the bladder (for curing bladder cancer).
Using with other drugs. Sometimes it is used in a combination with bacilli Calmette-Guerin (BCG) to cure bladder cancer, with aldesleukin (Proleukin®, IL-2) to treat melanomas and kidney cancer.
Side effects. Flu-like symptoms, pain, redness, itching or swelling, hair thinning, fatigue, fever, dizziness, loss of appetite, weight loss, diarrhea, difficulty sleeping, lowering numbers of white blood cells, red blood cells, and platelets.
Aldesleukin (Proleukin®, IL-2)
It is a medicinal form of IL-2 used to treat a kidney cancer and a skin cancer (melanoma).
How it works. IL-2 inhibits the growth and proliferation of cancer cells and stimulates them to send out substances that attract immune cells. The drug encourages the growth of killer T cells and other immune cells.
How is it made. It is synthetically produced by recombinant DNA techniques in bacteria E. coli with inserted an IL-2 gene from human white blood cells.
How it is given. As an injection just under the skin (daily for 5 days then 2 days rest for 4 weeks), into a vein (every eight hours for up to 15 doses).
Using with other drugs. Sometimes it is used with Interferon alfa-2b (Intron® A) to treat melanoma and kidney cancer.
Side effects. Vulnerability to infection, anemia, fatigue, breathlessness or a cough, drop in platelets, bruising (nosebleeds, bleeding gums, tiny red spots or bruises on arms or legs), flu-like symptoms (fever, chills, headaches), aching muscles and joints, confusion, depression, extreme sleepiness, low blood pressure, low urine output, weight gain, swelling in ankles, legs and face, a skin rash, diarrhea, loss of appetite, difficulty sleeping, feeling anxious or confused, a sore mouth, redness, swelling and soreness at the injection site.
See also: checkpoint inhibitors
Aldesleukin. Lexicomp Online® [updated 2015 Sep 1; cited 2015 Sep 10]. Lexi-Drugs®. Hudson, Ohio: Lexi-Comp, Inc.; Sep10, 2015.
Coico R, Sunshine G, Benjamini E (2003) Immunology: a short course. 5th ed. Wiley-Liss. pp. 153, 154, 161, 279, 281-283
Lodish H (2008) Molecular cell biology. 1st ed. New York: W.H. Freeman. pp. 580-581
Maus MV. Immunology: T-cell tweaks to target tumours. Nature. 2017 Feb 22. doi: 10.1038/nature21506.
Proleukin (aldesleukin) [package insert on the Internet]. San Diego (CA): Prometheus Laboratories Inc.; 2010 [updated 2015 Jan; cited 2015 Sep 10]. Available from: http://www.proleukin.com/assets/proleukin.pdf